CA2014659C - Composes pharmaceutiques pour le soulagement de la dysmenorrhee et (ou) du syndrome premenstruel et procede - Google Patents

Composes pharmaceutiques pour le soulagement de la dysmenorrhee et (ou) du syndrome premenstruel et procede

Info

Publication number: CA2014659C
Authority: CA; Canada
Prior art keywords: ibuprofen; composition; hctz; hydrochlorothiazide; dysmenorrhea
Prior art date: 1989-12-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002014659A

Other languages

English (en)

Other versions

CA2014659A1 (fr

Inventor

Howard Jones

Alison B. Lukacsko

Joseph Migliardi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-15

Filing date

1990-04-17

Publication date

1996-01-09

1989-12-15 Priority claimed from US07/452,022 external-priority patent/US5037823A/en

1990-04-17 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1991-06-15 Publication of CA2014659A1 publication Critical patent/CA2014659A1/fr

1996-01-09 Application granted granted Critical

1996-01-09 Publication of CA2014659C publication Critical patent/CA2014659C/fr

2010-04-17 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 17
206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 16
206010036618 Premenstrual syndrome Diseases 0.000 title claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
238000000034 method Methods 0.000 title description 7
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 74
229960001680 ibuprofen Drugs 0.000 claims abstract description 72
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 59
229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 59
239000000203 mixture Substances 0.000 claims abstract description 28
208000024891 symptom Diseases 0.000 claims abstract description 6
239000002831 pharmacologic agent Substances 0.000 claims abstract description 4
239000004480 active ingredient Substances 0.000 claims abstract description 3
239000002552 dosage form Substances 0.000 claims description 11
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical group OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 claims description 10
239000000739 antihistaminic agent Substances 0.000 claims description 10
230000001387 anti-histamine Effects 0.000 claims description 9
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 8
229940018203 pyrilamine maleate Drugs 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims 1
230000001882 diuretic effect Effects 0.000 description 20
ATOTUUBRFJHZQG-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 ATOTUUBRFJHZQG-UHFFFAOYSA-N 0.000 description 15
229960003357 pamabrom Drugs 0.000 description 15
239000000047 product Substances 0.000 description 14
239000002775 capsule Substances 0.000 description 13
239000003826 tablet Substances 0.000 description 13
239000002934 diuretic Substances 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
-1 acetamlnophen Chemical compound 0.000 description 9
230000029142 excretion Effects 0.000 description 9
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
229960001138 acetylsalicylic acid Drugs 0.000 description 8
239000008107 starch Substances 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
230000002485 urinary effect Effects 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000008187 granular material Substances 0.000 description 7
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
210000002700 urine Anatomy 0.000 description 7
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
239000011591 potassium Substances 0.000 description 5
229910052700 potassium Inorganic materials 0.000 description 5
229940069328 povidone Drugs 0.000 description 5
238000012360 testing method Methods 0.000 description 5
HNLAFWZKHCUIMC-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O HNLAFWZKHCUIMC-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
229960000582 mepyramine Drugs 0.000 description 4
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
230000036325 urinary excretion Effects 0.000 description 4
YMJMZFPZRVMNCH-FMIVXFBMSA-N 2-[methyl-[(e)-3-phenylprop-2-enyl]amino]-1-phenylpropan-1-ol Chemical compound C=1C=CC=CC=1/C=C/CN(C)C(C)C(O)C1=CC=CC=C1 YMJMZFPZRVMNCH-FMIVXFBMSA-N 0.000 description 3
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
229910003251 Na K Inorganic materials 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
208000004880 Polyuria Diseases 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
229960001948 caffeine Drugs 0.000 description 3
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
239000007894 caplet Substances 0.000 description 3
229960001750 cinnamedrine Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960000913 crospovidone Drugs 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
229960000905 indomethacin Drugs 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229940010990 pamabrom / pyrilamine Drugs 0.000 description 3
229960005489 paracetamol Drugs 0.000 description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
239000004205 dimethyl polysiloxane Substances 0.000 description 2
235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
230000001452 natriuretic effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
101100338494 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) hctB gene Proteins 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
101000856234 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Butyrate-acetoacetate CoA-transferase subunit A Proteins 0.000 description 1
101000856236 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Butyrate-acetoacetate CoA-transferase subunit B Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
101100338495 Oryza sativa subsp. japonica HCT2 gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
244000046127 Sorghum vulgare var. technicum Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
229960001040 ammonium chloride Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000003160 antidiuretic agent Substances 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
239000008406 cosmetic ingredient Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
SNDDIRAXSDUVKW-URVXVIKDSA-N dextromethorphan hcl Chemical compound Cl.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 SNDDIRAXSDUVKW-URVXVIKDSA-N 0.000 description 1
229960005257 dextromethorphan hydrochloride Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
229940008099 dimethicone Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
239000000374 eutectic mixture Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
229940082164 ibuprofen 50 mg Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229960000649 oxyphenbutazone Drugs 0.000 description 1
HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000009662 stress testing Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002014659A 1989-12-15 1990-04-17 Composes pharmaceutiques pour le soulagement de la dysmenorrhee et (ou) du syndrome premenstruel et procede Expired - Fee Related CA2014659C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US452,022		1989-12-15
US07/452,022 US5037823A (en)	1986-09-15	1989-12-15	Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process

Publications (2)

Publication Number	Publication Date
CA2014659A1 CA2014659A1 (fr)	1991-06-15
CA2014659C true CA2014659C (fr)	1996-01-09

Family

ID=23794697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002014659A Expired - Fee Related CA2014659C (fr)	1989-12-15	1990-04-17	Composes pharmaceutiques pour le soulagement de la dysmenorrhee et (ou) du syndrome premenstruel et procede

Country Status (1)

Country	Link
CA (1)	CA2014659C (fr)

1990
- 1990-04-17 CA CA002014659A patent/CA2014659C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2014659A1 (fr)	1991-06-15

Legal Events

Date	Code	Title	Description
1991-01-28	EEER	Examination request
2004-04-19	MKLA	Lapsed

Publication	Publication Date	Title
US5037823A (en)	1991-08-06	Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US4601894A (en)	1986-07-22	Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US7060730B2 (en)	2006-06-13	Rapidly absorbed liquid compositions
CA2182004C (fr)	2000-10-31	Comprimes enrobes de paracetamol et de domperidone
CZ101495A3 (en)	1996-02-14	Per os administered preparations with stably maintained release
IE61062B1 (en)	1994-09-21	Pharmaceutical composition containing ibuprofen and aluminium hydroxide
CZ287558B6 (en)	2000-12-13	Pharmaceutical preparation
JPS6241646B2 (fr)	1987-09-03
GB2281205A (en)	1995-03-01	Oral opioid analgesic
ES2197676T3 (es)	2004-01-01	Composiciones farmaceuticas que comprenden ibuprofeno y domperidona.
US5155105A (en)	1992-10-13	Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process
JPH0141608B2 (fr)	1989-09-06
JPH05246845A (ja)	1993-09-24	イブプロフェン含有解熱鎮痛剤
CA2014659C (fr)	1996-01-09	Composes pharmaceutiques pour le soulagement de la dysmenorrhee et (ou) du syndrome premenstruel et procede
CZ79593A3 (en)	1994-01-19	Antitussive preparation
JPH08239327A (ja)	1996-09-17	慢性骨格筋疼痛の予防又は治療剤
ES2285088T3 (es)	2007-11-16	Composiciones farmaceuticas de liberacion modificada.
NZ207768A (en)	1987-02-20	Sustained release tablets comprising dipyridamole
AU2011244930B2 (en)	2012-08-30	Rapidly absorbed liquid compositions
AU2008229913A1 (en)	2008-11-06	Rapidly absorbed liquid compositions
MXPA00005547A (en)	2002-07-25	Rapidly absorbed liquid compositions containing an amine and a nsaid